The Effects of Lapatinib and Trastuzumab in a Rat Model of Endometriosis

Year 2022, Volume: 43 Issue: 4, 556 - 563, 27.12.2022

Çağlar Yıldız Zeki Özsoy Turgut Kacan Hatice Özer

https://doi.org/10.17776/csj.1168698

Abstract

Trastuzumab and lapatinib are drugs belonging to tyrosine kinase inhibitors family that are used in cancer treatment to prevent cell proliferation. Trastuzumab is an inhibitor of human epidermal growth factor receptor–2 (HER2) tyrosine kinase, and lapatinib is an inhibitor of epidermal growth factor receptor (EGFR). Tyrosine kinase inhibitors have also been investigated for treatment of endometriosis. In the present study, we aimed to investigate the effects of lapatinib and trastuzumab on rat endometriosis model. Endometriosis was surgically induced by the autologous transplantation of endometrial tissue and formation of endometriosis was confirmed via secondary laparotomy in 32 rats. Initially, 4 mg/kg dose of trastuzumab was applied intraperitoneally, and two additional doses of 2 mg/kg were applied 7 days and 14 days after the initial dose. Lapatinib was administered as 100 mg/kg daily doses for 14 days. Rats were randomly divided into four groups and were subjected to lapatinib, trastuzumab, anastrozole (0.004 mg/day, p.o.) and normal saline (0.1 ml, i.p.) treatments for 14 days. Then, endometriosis foci were excised, and endometriosis scores were calculated in a semi-quantitative manner. Immunohistochemical (IHC) examinations were also performed using VEGF, CD117 and Bax antibodies. Both anastrozole and tyrosine kinase inhibitors lowered endometriosis scores. Significant decreases in ovarian follicle numbers were observed in lapatinib and anastrozole groups but not trastuzumab group. Lapatinib and trastuzumab decreased endometriotic foci through suppressing cell proliferation and promoting programmed cell death.

Keywords

Endometriosies, Lapatinib, Trastuzumab, Anastrozole, Tyrosine kinase inhibitors.

References

• [1] Giudice L.C., Endometriosis, Clinical practice, N. Engl. J. Med., 362 (25) (2010) 2389-98.
• [2] Harel Z., Dysmenorrhea in adolescents and young adults: an update on pharmacological treatments and management strategies, Expert Opin Pharmacother., 13 (15) (2012) 2157-70.
• [3] Simoens S., Dunselman G., Dirksen C., Hummelshoj L., Bokor A., Brandes I, et al., The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres, Hum. Reprod., 27 (5) (2012) 1292-9.
• [4] Jiang Q.Y., Wu R.J., Growth mechanisms of endometriotic cells in implanted places: a review, Gynecol Endocrinol., 28 (7) (2012) 562-7.
• [5] Nisolle M., Donnez J., Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities, Fertil Steril., 68 (4) (1997) 585-96.
• [6] Möller B., Rasmussen C., Lindblom B., Olovsson M., Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle, Mol Hum Reprod., 7 (1) (2001) 65-72.
• [7] Huang J.C., Papasakelariou C., Dawood M.Y., Epidermal growth factor and basic fibroblast growth factor in peritoneal fluid of women with endometriosis, Fertil Steril., 65 (5) (1996) 931-4.
• [8] Abe W., Nasu K., Tsuno A., Kawano Y., Narahara H., Phosphatidylinositol-3 kinase-Akt-mammalian target of rapamycin signaling pathway mediates contractility of human endometriotic stromal cells: A promising new target for the treatment of endometriosis-associated fibrosis, Gynecol Minim Invasive Ther., 3 (4) (2014) 115-8.
• [9] Melcher C.A., Janni J.W., Schneeweiss A., Fasching PA., Hagenbeck CD., Aktas B., et al. Abstract OT1-1-10: DETECT III - A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells, Cancer Res., 72 (2012) 1-10.
• [10] Blackwell K.L., Burstein HJ., Storniolo A.M., Rugo H., Sledge G., Koehler M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer, J Clin Oncol., 28 (7) (2010) 1124-30.
• [11] Vernon M.W., Wilson E.A., Studies on the surgical induction of endometriosis in the rat, Fertil Steril., 44 (5) (1985) 684-94.
• [12] Keenan J.A., Williams-Boyce P.K., Massey P.J., Chen T.T., Caudle M.R., Bukovsky A., Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole, Fertil Steril., 72 (1) (1999) 135-41.
• [13] Donnez J., Smoes P., Gillerot S., Casanas-Roux F., Nisolle M., Vascular endothelial growth factor (VEGF) in endometriosis, Hum Reprod., 13 (6) (1998) 1686-90.
• [14] Remmele W., Stegner H.E., Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (IRS) für den immunhistochemischen Ostrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue], Pathologe., 8 (3) (1987) 138-40.
• [15] Struble J., Reid S., Bedaiwy M.A. Adenomyosis: A clinical review of a challenging gynecologic condition. J. Minim. Invasive Gynecol. 23 (2) (2016) 164–185.
• [16] Bruner-Tran K.L., Mokshagundam S., Herington J.L., Ding T., Osteen K.G., Rodent Models of Experimental Endometriosis: Identifying Mechanisms of Disease and Therapeutic Targets, Curr Womens Health Rev., 14 (2) (2018) 173-188.
• [17] Kansu E., Hedeflenmiş tedavilerde "hedef" moleküller, ANKEM Derg., 19 (2005) 112-6.
• [18] Tokgönül H., Kuyucu Y., Mete U., Lapatinib’in sıçan over ve uterus dokuları üzerine olan etkilerinin ışık ve elektron mikroskobik düzeyde araştırılması, Cukurova Medical Journal, 45 (2020) 921-932.
• [19] Chen H.X., Cleck J.N., Coelho R., Dancey J.E., Epidermal growth factor receptor inhibitors: current status and future directions, Curr Probl Cancer., 33 (4) (2009) 245-94.
• [20] Li-Ping Z., Da-Lei Z., Jian H., Liang-Quan X., Ai-Xia X., Xiao-Yu D. et al., Proto-oncogene c-erbB2 initiates rat primordial follicle growth via PKC and MAPK pathways, Reprod. Biol. Endocrinol., 8 (66) (2010) 1-9.
• [21] Sağsöz H., Ketani M.A., Saruhan B.G., Expression of the erbB/HER receptor family in the bovine uterus during the sexual cycle and the relation of this family to serum sex steroids, Biotech Histochem., 87 (2) (2012) 105-16.
• [22] Imai A., Takagi A., Tamaya T., Gonadotropin-releasing hormone analog repairs reduced endometrial cell apoptosis in endometriosis in vitro, Am. J. Obstet. Gynecol., 182 (5) (2000) 1142-6.
• [23] Meresman G.F., Augé L., Barañao R.I., Lombardi E., Tesone M., Sueldo C., Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis, Fertil Steril., 77 (6) (2002) 1141-7.
• [24] Meresman G.F., Bilotas M., Abello V., Buquet R., Tesone M., Sueldo C., Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis, Fertil Steril., 84 (2) (2005) 459-63.
• [25] Carmeliet P., Jain R.K., Angiogenesis in cancer and other diseases, Nature., 407 (6801) (2000) 249-57.
• [26] Risau W., Mechanisms of angiogenesis, Nature., 386 (6626) (1997) 671-4.
• [27] Xu H., Zhang T., Man G.C., May K.E., Becker C.M., Davis T.N., et. al., Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis, Angiogenesis., 16 (3) (2013) 541-51.
• [28] Bilotas M., Meresman G., Stella I., Sueldo C., Barañao R.I., Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis, Fertil Steril., 93 (8) (2010) 2513-8.
• [29] Spector N.L., Blackwell K.L., Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer, J Clin Oncol., 27 (34) (2009) 5838-47.
• [30] Wingfield M., Macpherson A., Healy D.L., Rogers P.A., Cell proliferation is increased in the endometrium of women with endometriosis, Fertil Steril., 64 (2) (1995) 340-6.
• [31] Pacchiarotti A., Caserta D., Sbracia M., Moscarini M., Expression of oct-4 and c-kit antigens in endometriosis, Fertil Steril., 95 (3) (2011) 1171-3.
• [32] Yildiz C., Kacan T., Akkar O.B., Karakus S., Kacan S.B., Ozer H., et al. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats, Reprod Sci., 22 (11) (2015) 1445-51.
• [33] Harada T., Kaponis A., Iwabe T., Taniguchi F., Makrydimas G., Sofikitis N., et al. Apoptosis in human endometrium and endometriosis, Hum Reprod Update., 10 (1) (2004) 29-38.
• [34] Dmowski W.P., Ding J., Shen J., Rana N., Fernandez B.B., Braun D.P., Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis, Hum Reprod., 16 (9) (2001) 1802-8.
• [35] Konecny G.E., Venkatesan N., Yang G., Dering J., Ginther C., Finn R., et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells, Br J Cancer., 98 (6) (2008) 1076-84.
• [36] Wainberg Z.A., Anghel A., Desai A.J., Ayala R., Luo T., Safran B., et al., Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo, Clin Cancer Res., 16 (5) (2010) 1509-19.
• [37] Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N Engl J Med., 355 (26) (2006) 2733-43.
• [38] Barbieri R.L., Hormone treatment of endometriosis: the estrogen threshold hypothesis, Am J Obstet Gynecol., 166 (2) (1992) 740-5.
• [39] Oral E., Demir B., Inceboz U., Endometriosis and ovarian reserve, Womens Health., 11 (5) (2015) 671-5.